Brief: Anavex Receives FDA Clearance Of Its Ind Application For Blarcamesine In Fragile X Syndrome
15/10/2026 22:00
BRIEF-Anavex Receives FDA Clearance Of Its Ind Application For Blarcamesine In Fragile X Syndrome Oct 15 (Reuters) - Anavex Life Sciences Corp AVXL.O:
ANAVEX RECEIVES FDA CLEARANCE OF ITS IND APPLICATION FOR BLARCAMESINE IN FRAGILE X SYNDROME
ANAVEX LIFE SCIENCES CORP - IND FOR BLARCAMESINE IN FRAGILE X SYNDROME NOW OPEN IN THE U.S.
ANAVEX LIFE SCIENCES CORP - PHASE 2A STUDY TO EVALUATE BLARCAMESINE IN ADULT MALES WITH FRAGILE X SYNDROME
Source text: ID:nGNX1jDqcY
Further company coverage: AVXL.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Anavex Life Sciences
See all newsBrief: Anavex Provides Corporate Update, Announces Completion Of Clinical Conduct Of Adme And Ddi Clinical Studies
Brief: Anavex Receives FDA Clearance Of Its Ind Application For Blarcamesine In Fragile X Syndrome
Brief: Glass Lewis Recommends Anavex Stockholders To Vote For PVG’s Director Nominees
Brief: PVG Calls For Replacing Anavex Board, Hiring "Experienced" CEO
Brief: Pvg Asset Management- Nominates Six Director Candidates For Anavex Board